Molecular Oncology · 2021 · 13 citations · 48 references
MedicineCancer BiologyOncologyGastrointestinal OncologyMolecular OncologyNeoplasiaCancer Cell SignalingColorectal CancerMalignant NeoplasmsMolecular Tumor ProfilingOncogenic Signaling PathwaysSignal Transduction In CancerConfocal Fluorescence MicroscopyErk SignalingPhosphatidylinositol 3-Kinase-akt PathwayPhosphoinositide 3-Kinase-akt ActivationPhosphoinositide 3-Kinase-akt SignalingPi3k SignalingPi3k-akt Signaling PathwaySox9 Regulation
KRAS is a gatekeeper gene in human colorectal tumorigenesis. KRAS is 'undruggable'; hence, efforts have been diverted to inhibit downstream RAF/MEK/ERK and PI3K/Akt signaling. Nevertheless, none of these inhibitors has progressed to clinical use despite extensive trials. We examined levels of phospho-ERK1/2(T202/Y204) and phospho-Akt1/2/3(S473) in human colorectal tumor compared to matched mucosa with semi-quantitative near-infrared western blot and confocal fluorescence immunohistochemistry imaging. Surprisingly, 75.5% (25/33) of tumors had lower or equivalent phospho-ERK1/2 and 96.9% (31/32) of tumors had lower phospho-Akt1/2/3 compared to matched mucosa, irrespective of KRAS mutation status. In contrast, we discovered KRAS-dependent SOX9 upregulation in 28 of the 31 (90.3%) tumors. These observations were substantiated by analysis of the public domain transcriptomics The Cancer Genome Atlas (TCGA) and NCBI Gene Expression Omnibus (GEO) datasets and proteomics Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset. These data suggest that RAF/MEK/ERK and PI3K/Akt signaling are unlikely to be activated in most human colorectal cancer.
48
HTSeq—a Python framework to work with high-throughput sequencing data
Simon Anders, Paul Theodor Pyl, Wolfgang Huber · Bioinformatics · 2014 · 22.7K citations · Full text